Colorectal Mucinous Adenocarcinoma
Associated Genetic Biomarkers
NCI Definition: An invasive colorectal adenocarcinoma characterized by the presence of extracellular mucin pools that contain malignant glandular epithelial structures. The extracellular mucin pools occupy more than 50% of the malignant lesion. 
Colorectal mucinous adenocarcinomas most frequently harbor alterations in KRAS, APC, TP53, BRAF, and SMAD4 .
KRAS Mutation, KRAS Exon 2 Mutation, APC Mutation, KRAS Codon 12 Missense, and TP53 Mutation are the most common alterations in colorectal mucinous adenocarcinoma .
There is 1 clinical trial for colorectal mucinous adenocarcinoma, of which 0 are open and 1 is completed or closed. Of the trial that contains colorectal mucinous adenocarcinoma as an inclusion criterion, 1 is phase 2 (0 open).
Microsatellite is the most frequent gene inclusion criterion for colorectal mucinous adenocarcinoma clinical trials .
Ipilimumab and nivolumab are the most common interventions in colorectal mucinous adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.